AIM ImmunoTech Inc. (AIM) is an immunotherapeutic firm developing R&D for therapies to cure different cancers types, immunological diseases, and diseases caused by SARS-CoV-2. The company’s shares swelled by 4.85% to remain at $1.08 at the closing of Friday’s regular trading session. The price further boomed by 29.6% in the premarket session on Monday. The current stock price as of the writing stands at $1.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
AIM: Recent Developments
AIM stated on April 11 regarding the data presented from the Phase 2 clinical trials assessing the company’s pipeline candidate, Ampligen or rintatolimod as a constituent of treatment for colorectal cancer at the 2022 Annual Meeting of the American Association for Cancer Research. Also, the company updated on optimistic data Phase 1 trial of Ampligen, interferonα-2b, and pembrolizumab for metastatic triple-negative breast cancer patients using chemokine modulation therapy at the 2022 Annual Meeting of AACR.
AIM: Industry Outlook
There is a wide-ranging influence of the pandemic on the international immunology producers. The market shrank as a result of shifting of all resources towards potential treatment and prevention of the COVID-19 virus, the rest of the market shrank as demand weakened. There was reduced growth in the international market (just 4.2%) during 2020 but now shifting to pre-pandemic stages. The international immunology market is anticipated to grow at a CAGR of 8.1% to reach $158.69 billion by 2028.
AIM: Company Outlook
For the year ended December 31, 2021, AIM recorded an EPS of -$0.40 for the full fiscal year 2021. The cash and cash equivalents that drive the company’s research and development activities for upcoming quarters are $48.3 million. A lot of activity happened in the last few months ranging from the acceptance of its abstracts for presentation at key conferences to getting IND clearance from the FDA to Ampligen for treating locally advanced pancreatic cancer.
AIM stock is 4% up year-to-date. Its potential to vigorously grow recently is likely attributed to the solid pipeline of the company along with the investor’s interest. The recent premarket stock gain is associated with the positive data of Phase 2 trials of Ampligen to treat colorectal cancer and metastatic triple-negative breast cancer.